Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
Lucy Cook, Gillian O’Dell, Eleni Vourvou, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 15

Showing 15 citing articles:

Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M. Baptiste, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 14, pp. 1699-1721
Closed Access | Times Cited: 20
Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering
Yunji Liao, Hang Ma, Zhenyu Wang, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 6
Open Access
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia
Annalisa Chiarenza, Gaia Vertillo Aluisio, Nunziatina Laura Parrinello, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients
Vincenzo Raimondi, Paola Storti, Rosanna Vescovini, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
Quincy Hofsink, Sabine Haggenburg, Birgit I. Lissenberg‐Witte, et al.
EClinicalMedicine (2023) Vol. 61, pp. 102040-102040
Open Access | Times Cited: 12
Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients
Takaaki Konuma, Megumi Hamatani-Asakura, Etsuko Nagai, et al.
International Journal of Hematology (2024) Vol. 120, Iss. 2, pp. 229-240
Open Access | Times Cited: 1
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
José Luís Piñana, Lourdes Vázquez, Inmaculada Heras, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
Mary J. Kasten, Brian D. Lahr, Anusha Parisapogu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Parent Acceptance toward Inactivated COVID-19 Vaccination in Children with Acute Lymphoblastic Leukemia: The Power of Oncologist and Alliance
Yifei Ma, Nianqi Liu, Guanqing Zhong, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2016-2016
Open Access | Times Cited: 5
One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic
Ondrej Šušol, Barbora Šušolová, Ondřej Klempíř, et al.
Cancer Medicine (2024) Vol. 13, Iss. 24
Open Access
Blood Disorders: Response and Achille Heel in the Framework of SARS-Cov-2- a Short Review
Maria Giovanna Buonomenna
Elsevier eBooks (2024), pp. 455-466
Closed Access
Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study
Jean‐François Rossi, Emmanuel Bonnet, Christel Castelli, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 493-493
Open Access | Times Cited: 1
Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS‐CoV‐2 Omicron in patients with haematological malignancies: A national prospective cohort study
Lukas Kevličius, Karolis Šablauskas, Kazimieras Maneikis, et al.
British Journal of Haematology (2023) Vol. 204, Iss. 2, pp. 497-506
Open Access | Times Cited: 1
Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts
Erina Takagi, Seitaro Terakura, Hidetsugu Fujigaki, et al.
International Journal of Hematology (2023) Vol. 118, Iss. 4, pp. 462-471
Closed Access
Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies
Chien-Tzu Huang, Ching-Ping Lee, Tzu‐Yin Chen, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 17, pp. 5647-5647
Open Access
Page 1

Scroll to top